Search Results
Found 42 results for "belgium" across articles, medicines, trials, companies and the glossary
MedicinesAll 33 →
Accusol 35 Potassium 2 mmol/lSolution for haemofiltration, haemodialysis and haemodiafiltrationSodium chloride, Calcium chloride, Magnesium chloride, Sodium bicarbonate, Potassium chloride · Nikkiso Belgium bvba
Accusol 35 Potassium 4 mmol/lSolution for haemofiltration, haemodialysis and haemodiafiltrationSodium chloride, Calcium chloride, Magnesium chloride, Sodium bicarbonate, Potassium chloride · Nikkiso Belgium bvba
Accusol 35 Solution for haemofiltration, haemodialysis and haemodiafiltrationSodium chloride, Calcium chloride, Magnesium chloride, Sodium bicarbonate · Nikkiso Belgium bvba
Biphozyl Solution for haemodialysis/haemofiltrationMagnesium chloride hexahydrate, Sodium chloride, Sodium hydrogen carbonate, Potassium chloride, Disodium phosphate dihydrate · Vantive Belgium SRL
Dianeal PD4 Glucose 1.36 % w/v (13.6 mg/ml), Solution for peritoneal dialysisGlucose anhydrous, Glucose monohydrate, Sodium chloride, Sodium lactate, Calcium chloride dihydrate ph. eur. · Vantive Belgium SRL
Dianeal PD4 Glucose 2.27 % w/v (22.7 mg/ml), Solution for peritoneal dialysisGlucose anhydrous, Glucose monohydrate, Sodium chloride, Sodium lactate, Calcium chloride dihydrate · Vantive Belgium SRL
Pharmaceutical
Ireland's Eight-Year Citizenship Rule: A Talent-Retention Problem for Pharma, Biotech and MedTech
Ireland built a life-science powerhouse by being the easiest place in Europe for global talent to land and stay. The proposed move from five to eight years for citizenship changes the terms on which the sector's skilled workforce agreed to come here. This analysis looks at what it means for engineers and scientists on Critical Skills permits, for the companies that depend on them, and what a fairer Bill would look like.
Industry
Ireland's Eight-Year Citizenship Rule: Why It Risks Punishing the Nurses, Carers and Pharma Professionals the Country Cannot Do Without
The Government wants to raise the residency requirement for Irish citizenship from five years to eight, with language and civics tests on top. This analysis looks at who actually carries the weight of that change: the internationally trained nurses, care assistants and pharmaceutical professionals who keep Irish hospitals, nursing homes and manufacturing plants running, and how Ireland would compare with Canada, Australia and the rest of Europe.
Industry
The Resource Equation: Decoupling Water, Power, and the Shift in Ireland’s Data Centre and Life Sciences Footprint
An in-depth, fact-based analysis of water and power consumption across Ireland’s twin industrial pillars, the infrastructure bottlenecks, and the shifting geography of high-tech construction.
Industry
The €8.5 Billion Defense: Dutch Innovative Pharma Fights Back Against Cost-Control Policies
The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s €8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.
Regulatory Affairs
GEODIS Expands Pharmaceutical Logistics in Poland: Securing Dual GDP and IATA CEIV Pharma Certifications
GEODIS has renewed its IATA CEIV Pharma accreditation in Warsaw and secured GDP certification for its Stryków Dobra contract logistics facility. This dual compliance milestone bolsters Poland’s status as a critical gateway in Europe’s pharmaceutical supply chain.
Pharmaceutical
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector
An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.
Biotechnology
Rare Disease Bottlenecks vs. Encouraging Clinical Trial Growth in Ireland
Despite encouraging growth in clinical trial activity, patients in Ireland face an average wait of 801 days for access to rare disease medicines, prompting calls for urgent systemic reform.
Industry
Europe's United Front: How the Beneluxa Initiative is Defending the Pharma Framework Against US Pricing Pressure
With the US pushing for individual drug pricing deals and Germany slashing healthcare spending, the Beneluxa Initiative represents five European nations calling for a unified, coordinated approach to protect Europe's pharmaceutical innovation and access to medicines in 2026.